-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Upgrades BioNTech to Buy, Raises Price Target to $135

Benzinga·05/27/2026 18:11:34
Listen to the news
UBS analyst David Dai upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price target from $117 to $135.